The usual disclaimer: I’m not investment advice. I hold $XBI. With thanks to Carl West for editing and feedback. In case you don’t know, the biotech market is down. Like, really down. With the biotech rout in the public markets, I wondered whether there are any trends that can be pulled out of the plungeContinue reading “What ate the public biotech market?”
Category Archives: biotechnology
The promise of phage therapy
Against the threat of antibiotic resistant infections, the future is phage.
Natalie Jing Ma, PhD 